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Abstract
Genetic redundancy poses a major problem to the analysis of gene function. RNA interference allows the down-
regulation of several genes simultaneously, offering the possibility to overcome genetic redundancy, something not
easily achieved with traditional genetic approaches. Previously we have used a polycistronic miR155-based
framework to knockdown expression of three genes of the early B cell factor family in cultured cells. Here we develop
the system further by generating transgenic mice expressing the RNAi construct in vivo in an inducible manner.
Expression of the transgene from the strong CAG promoter is compatible with a normal function of the basal miRNA/
RNAi machinery, and the miR155 framework readily allows inducible expression from the Rosa26 locus as shown by
Gfp. However, expression of the transgene in hematopoietic cells does not lead to changes in B cell development
and neuronal expression does not affect cerebellar architecture as predicted from genetic deletion studies. Protein as
well as mRNA levels generated from Ebf genes in hetero- and homozygous animals are comparable to wild-type
levels. A likely explanation for the discrepancy in the effectiveness of the RNAi construct between cultured cells and
transgenic animals lies in the efficiency of the sequences used, possibly together with the complexity of the
transgene. Since new approaches allow to overcome efficiency problems of RNAi sequences, the data lay the
foundation for future work on the simultaneous knockdown of several genes in vivo.
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Introduction
One of the surprising findings of gene targeting in mice are
knock-out animals with no obvious phenotype. While a
proportion of these cases is likely due to incomplete phenotypic
testing or a manifestation only under certain non-standard
conditions, it is estimated that 10 - 15% of knock-out mice do
not have an obvious phenotype [1]. The vast majority of such
cases is thought to derive from functional redundancy between
duplicated and highly homologous genes [2]. In favour of this
hypothesis, duplicate genes occur in all organisms, especially
in multicellular eukaryotes with approximately 50% of mouse
genes having a related member in the genome [3–5]. While
these facts have interesting and sometimes hard to reconcile
implications for evolutionary biology [6,7], gene duplications
and redundancy often mask the true contribution of single
genes, making it difficult to discern the function of each copy by
knocking out individual genes [8].
Interestingly, conserved gene duplicates in vertebrates are
specifically enriched for signal transduction and developmental
function [9]. Good examples of this are the MRF family of
transcription factors, acting as master regulators of vertebrate
skeletal muscle development, and the Hox gene cluster [10].
Another interesting case is the early B cell factor (Ebf) family of
transcription factors. All four members show a high level of
sequence conservation, reaching 80 - 90% at the nucleotide
level within conserved domains, and all four members bind to
the same DNA sequence [11,12]. Despite a strong expression
in tissues like the olfactory epithelium and in many neuronal
cells, deletion of Ebf1 results in a distinct phenotype, i.e. the
complete block of early B cell development [13]. This finding
was unexpected, but Ebf1 is the only family member expressed
in hematopoietic cells, whereas the tissues mentioned above
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express other Ebf genes in a largely overlapping manner
[14–17]. In fact, in addition to B cells, Ebf1 is the only Ebf gene
expressed in the embryonic striatum and in cranial nerve
nuclei, and Ebf1-deficient mice display atrophy and abnormal
cellular migration, axonal fasciculation and projection [18–20].
Ebf2 and Ebf3 are also expressed in a largely overlapping
pattern, and deletion of the single genes leads to a mixture of
distinct and overlapping phenotypes causing lethality at the age
of approximately two months or immediately after birth
respectively. Ebf2 null mice display abnormalities in the
cerebellum and peripheral nerve [21,22]. Mice double
heterozygous for Ebf2 and Ebf3 recapitulate common defects,
such as defective projection of olfactory neurons, but do not
display some of the defects occurring only in single knock-outs,
arguing that the function of Ebf genes is dose-dependent and
at least partially redundant [23].
In an effort to overcome functional redundancy and examine
the contribution of Ebf factors in general to the support of
hematopoietic stem cells, we employed the SIBR (synthetic
inhibitory BIC-derived RNA) vectors, a new approach to down-
regulate several genes simultaneously based on RNA
interference [24]. In this system shRNA sequences are
embedded into the framework of miR155/BIC including the
flanking sequences, which are cleaved by the RNAseIII
enzyme Drosha. This allows the concatemerisation of several
shRNAs, and the inclusion of a marker gene, in our case Gfp.
Furthermore, regulated expression of the RNAi construct is
possible since it uses RNA polymerase II-driven promoters.
Overall, this results a flexible system to express several
shRNAs together with a marker gene in a single polycistronic
mRNA driven by PolII [25]. We were able to successfully down-
regulate Ebf1, Ebf2 and Ebf3 and to demonstrate redundancy
between these genes in retrovirally infected cultures of
osteoblastic cells [24]. The same vector has been used also by
other groups to inhibit the Ebf proteins in a variety of different
cells [26,27]. As this system proved useful in cell culture
approaches in different contexts, we wanted to develop it
further and overcome the limitations of in vitro approaches and
retroviral infections. Here, we report the generation of
transgenic mice with a targeted insertion of the SIBR-based
EbfRNAi construct into the murine Rosa26 locus, and describe
the effects of its induced expression.
Results
Generation of EbfmiRNA transgenic mice
The successful down-regulation of Ebf1, Ebf2 and Ebf3 using
one miRNA construct allowed us to analyse the biological
effects of this highly conserved protein family in cell culture
[24]. While this approach opens new possibilities in studying
biological roles independent of redundancy, it remains limited
to in vitro assays and the expression of the miRNA construct
via transfection or viral infection. To overcome these limitations
we wanted to develop this system further and use it in vivo by
generating mice with a targeted insertion. We had previously
generated two different miRNA constructs, RNAi-a and RNAi-b,
targeting the mRNAs of Ebf1, Ebf2 and Ebf3 at different
positions, primarily to control for off-target effects of the miRNA
generated [24,28]. The single shRNAs bind to regions of the
Ebf mRNAs corresponding to the DNA binding or the adjacent
IPT/TIG-domain (of unknown function) of the encoded proteins
(Figure S1A) and are concatemerised as indicated (Figure
S1B). Therefore, as two different constructs were available, we
wanted to analyse the effectiveness of the RNAi constructs in
detail before going in vivo. Therefore, HEK293T cells were
transfected with expression plasmids for flag-tagged Ebf1, Ebf2
and Ebf3. In parallel, all six single constructs (two per Ebf
gene), double and triple constructs were co-transfected. Co-
expression of the single RNAi constructs resulted in the down-
regulation of the respective Ebf protein, but left the other family
members relatively unaffected, indicating specificity but also a
high level of effectiveness. The double RNAi constructs against
Ebf2 and Ebf3 led to their strong down-regulation, but left Ebf1
relatively unchanged, demonstrating that neither specificity nor
effectiveness are compromised by the concatemerisation via
the flanking region of miR155. Finally, expression of the triple
RNAi constructs induced a loss of Ebf proteins to almost
undetectable levels (Figure S2). Although the single RNAi
constructs seemed to show slight differences in down-
regulation efficiencies, these were minor and could be due to
experimental variances. In fact, no differences were observed
with the double and triple constructs, confirming data from the
down-regulation of endogenous Ebf proteins [24]. Therefore,
we decided to use both constructs for the generation of
targeted mouse ES cells.
Since miRNAs are standard class II mRNAs driven by RNA
polymerase II [29], yet depend on strong expression, we
decided to target the insertion to the Rosa26 locus. However,
instead of relying on the endogenous transcriptional activity of
the locus we decided to use the synthetic CAG (CMV early
enhancer/ chicken β-actin) promoter, which has very strong
transcriptional activity [30,31]. In combination with a
transcriptional Stop site and a PGK::Neo resistance cassette,
both flanked by loxP sites, immediately downstream of the
CAG promoter (Figure 1A), this construct allows strong and
tissue-specific expression of the insert [32]. The insert, which
follows immediately after the loxP sites consists of the Gfp
gene and the short hairpin sequences concatemerised by the
flanking region of miR155 (Figure 1A). This sequence was cut
from the pcDNA6.2-GW/EmGFP vector that was described
before [24], and is also analysed here (Figure S2).
The targeting construct was used for electroporation of
IDG3.2 murine ES cells, which were selected by G418. 600
resistant ES cell clones were picked and analysed for correct
integration of the construct by Southern blot. In case of the
external 5' probe, the appearance of a 6kb band in an EcoRI
digestion and of a 12 kB band with a ScaI digestion indicates
the correct integration of the construct. Figure 1B shows two
clones with integration of the RNAi-A (A-xx) and two clones
with integration of the B construct (B-xx). Hybridising Southern
Blot to the internal Gfp probe results in the predicted bands of 3
kb for the EcoRI digest and 12 kb for the ScaI digest,
confirming the correct and unique integration of the targeting
vector (Figure 1C). In addition to the Southern Blot, all positive
clones were also confirmed by sequencing. Overall, a 7.5%
targeting efficiency was achieved over 600 clones tested,
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Figure 1.  Generation of EbfmiRNA transgenic murine ES cells.  (A) Schematic representation of the Rosa26 wild-type locus. A
solid line represents regions involved in the targeting construct, while a dashed line depicts genomic regions beyond the targeting
construct. The targeting strategy consists of inserting the transgene into the XbaI site in intron 1, which is flanked by homology arms
including exons1, 2 and 3. The transgene consists of the synthetic CAG-promoter, a PGK::Neo cassette with a transcriptional Stop
sequence flanked by loxP sites, the RNAi insert as a black box, and a polyA sequence. In the third line the insert is detailed as
consisting of the Gfp gene, and DNA sequences encoding for short hairpin mRNA against Ebf3, Ebf2 and Ebf1. These sequences
are surrounded by the flanking region of miR155, which is recognised by the ribonuclease Drosha. The locus after recombination is
depicted in line 4, also indicating the direction of transcription from the CAG promoter and the PGK::Neo-Stop cassette.
Endogenous and newly introduced restriction sites are indicated and the resulting fragment lengths for wild-type and targeted allele
with specific restriction enzymes are given. Southern blot probes corresponding to the 5’ region and to the Gfp gene are indicated.
(B) Southern blot of genomic DNA from one wild-type and four mutant ES cell clones digested with EcoRI and ScaI as indicated,
and hybridised to the 5´ probe (as shown in A). Bands corresponding to the wild-type (wt) and the targeted (int) allele are indicated.
(C) Southern blot of genomic DNA as in B, hybridised to the internal Gfp probe. Bands of the correct size appear in all four targeted
ES cell clones as indicated.
doi: 10.1371/journal.pone.0080312.g001
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confirming the high recombination efficiency published for this
locus [33,34].
No leakiness and high inducibility of the transgene in
murine ES cells
To test the transgene functionally before going in vivo, we
transfected ES cell clones with the pGK-cre-bpA plasmid (kind
gift of Dr. Kurt Fellenberg, Institute of Genetics, University of
Cologne), which leads to the expression of the Cre-
recombinase in transfected cells. In consequence, the
transcriptional Stop sequence should be deleted and the
transgene including the Gfp gene should come under control of
the CAG promoter (Figure 2A). ES cells were harvested 48h
post-transfection and analysed by flow cytometry for the
expression of Gfp. Figure 2B indicates that cells transfected
with the mock vector do not express Gfp, and a low percentage
of cells shows apoptosis as detected by propidium iodide.
Transfection of the Cre-encoding plasmid however, leads to an
expression of Gfp in approximately 30% of cells, again with a
low percentage of cells showing apoptosis (Figure 2B). This
indicates that the construct is not leaky, i.e. there is no
expression of the transgene in presence of the Stop sequence,
and that the transgene is efficiently induced via Cre-mediated
excision of the Stop cassette. Furthermore, expression of the
transgene does not influence viability of the cells.
No leakiness, high inducibility and strong expression
of the transgene in vivo
Since all tests in ES cells provided evidence for the correct
insertion and the functioning of the transgene, we proceeded to
generate transgenic mice by standard conditions. Two different
ES cell clones for each RNAi construct were injected into
blastocysts and chimeric mice were obtained with both
transgenic constructs, RNAi-a and RNAi-b. However, germ-line
transmission was only successful with chimeric mice transgenic
for the RNAi-a construct. As RNAi-a and RNAi-b did not differ
significantly in their ability to down-regulate Ebf proteins in vitro
(Figure S2 and [24]), we continued to analyse these mice and
will refer to them as Rosa26RNAi.
To determine leakiness, inducibility and functionality in vivo,
we wanted to induce expression of the transgene in
hematopoietic cells. Ebf1 is expressed in early B cells and is
necessary for the transition from fraction A to fraction B during
B cell development [13]. Furthermore, miRNAs and the protein
machinery required for their processing are important for the
development of other hematopoietic cells like T and B cells
[35]. Thereby, the functionality of the transgene can be tested
in early B cells and potentially unspecific or off-target effects by
examining T cell development, making the hematopoietic
system ideal to study both aspects. To this end, we crossed the
Rosa26RNAi mouse line to the vavCre line, which is active in
hematopoietic stem cells and their derivatives [36]. In a first
analysis, we wanted to determine the inducibility and the level
of expression of the transgene, as these are two critical
parameters for the effectiveness of RNAi. Single cell
suspension from the bone marrow of adult mice from various
genotypes was analysed by flow cytometry for the expression
of Gfp. In all control mice, wt::wt, wt::Rosa26RNAi/+ and
vavCre::wt, no expression of Gfp and a percentage of
approximately 50% B220-positive cells could be detected,
indicating again no leakiness of the construct. A small
reduction in the number of B220-positive cells was observed in
the presence of the recombinase, but this phenotype did not
reach statistical significance, therefore it might represent a
slight tendency, but does not proof phenotypic changes due to
the expression of the Cre recombinase. The vast majority of
bone marrow from vavCre::Rosa26RNAi/+ is shifted into the Gfp
positive channel, with virtually all B220-positive cells also
expressing Gfp. The level of expression of Gfp varies between
several different populations, but ranges between one to three
shifts in logarithmic units above wild-type, with the majority of
cells at around two log-shifts (Figure 3A). Bone marrow cells
from vavCre::Rosa26RNAi/RNAi show exactly the same pattern of
Gfp-positive cells when plotted against B220, but the
expression of Gfp is shifted to even higher levels, with very few
cells remaining negative for Gfp (Figure 3A). Statistical analysis
shows that the described differences in the expression of Gfp
are highly significant, and also indicate that the number of
B220-positive cells is reduced from 53.8% in wild-type animals
to 40.4% in vavCre::Rosa26RNAi/+ and 38.6% in
vavCre::Rosa26RNAi/RNAi mice, indicating a potential but weak
influence of the transgene on B cell development (Figure 3B).
No alterations in early B cell fractions mediated by
expression of the transgene
As we detected a high expression of the transgene,
particularly in B cells and a slight reduction of B220-positive
cells, we continued to analyse the functionality of the RNAi
transgene. Since Ebf1 is the only Ebf family member
expressed in haematopoietic cells and is required for the
progression from fraction A to fraction B in early B cell
development [13], we expected a block or at least a down-
regulation of cells in the transition from fraction A to fraction B,
depending on the efficiency of the construct. Single cell
suspensions from mice of the indicated genotypes were
stained for B220 and CD43, and double positive cells, which
comprise fractions A - C were analysed. No differences in the
percentage of these cells were detected (Figure S3). For
further analysis, these cells were gated and analysed for
expression of BP-1 and CD24, allowing the individual fractions
to be distinguished. Again, no differences beyond standard
variations in fractions A (BP-1-CD24-), B (BP-1-CD24+), or C
(BP-1+CD24+) could be detected in the various genotypes
(Figure 4A). Statistical analysis confirms this for all fractions
tested. Neither in the B220+CD43+ Fractions A - C, nor in the
individual fractions is it possible to detect any significant
changes (Figure 4B).
Expression of the transgene does not interfere with
Ebf1 levels in vivo
As no differences in early B cell fractions could be detected
in hematopoietic cells, yet the cells express the transgene, we
wanted to determine the levels of Ebf1 under these conditions.
Therefore, we sorted fractions A, B and C according to the
sorting gates indicated in Figure 5 A from mice carrying the
same genotypes as before. Analysis of these early B cell
Multi-Gene Knockdown by RNAi
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Figure 2.  The transgene shows no leakiness and high inducibility in murine ES cells.  (A) Schematic depiction of the
transgene inserted into the Rosa26 locus. Expression is driven by the strong CAG promoter, but aborted due to the presence of the
transcriptional Stop sequence. Upon Cre mediated deletion, the stop cassette is removed and a polycistronic mRNA encoding for
Gfp and short-hairpin sequences against Ebf3, Ebf2 and Ebf1 gets expressed. (B) ES cell clones tested by Southern blot as
correctly targeted for either the RNAi-a or RNAi-b construct were transfected with the pGK-Cre-bpA plasmid encoding for the Cre
recombinase or with the empty parental vector (mock). 48 h after transfection, cells were analysed by FACS for the expression of
Gfp and for cell death by propidium iodide. Cells have been gated for FSC/SSC.
doi: 10.1371/journal.pone.0080312.g002
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Figure 3.  No leakiness, high inducibility and strong expression of the transgene in vivo.  (A) Single cell suspensions from
bone marrow of mice with the indicated genotypes were analysed for the expression of Gfp and the B cell marker B220. Gfp-positive
cells are observed only in combination of the vavCre and the transgenic Rosa26RNAi genotypes. All other genotypes show expression
of B220, but a lack of Gfp. Note the slight shift in expression of Gfp from Rosa26RNAi/+ to Rosa26RNAi/RNAi, due to the presence of two
alleles of the transgene. Cell have been gated for FSC/SSC and as PI-. (B) Statistical analysis of bone marrow cells stained and
analysed as in A. Significant differences based on genotypes are observed only in combination of the vavCre and Rosa26RNAi
transgenes compared to all other genotypes; n=3-4; error bars=SD; ** p<0.01, *** p<0.001.
doi: 10.1371/journal.pone.0080312.g003
Multi-Gene Knockdown by RNAi
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Figure 4.  No alterations in early B cell fractions mediated by expression of the transgene.  (A) Single cell suspensions from
bone marrow of mice with the indicated genotypes were analysed for the percentage of early B cell fractions. Cells were stained
with propidium iodide, B220, CD43, BP-1, HSA and CD24. Propidium iodide negative cells are gated as B220/CD43 double positive
(see Figure S3), and analysed for expression of HSA/CD24 allowing to distinguish fractions A (B220+CD43+CD24-BP-1-), B
(B220+CD43+CD24+BP-1-) and C (B220+CD43+CD24+BP-1+) of B cell development. Representative examples of the indicated
genotypes are shown. Cells were further gated for FSC/SSC. (B) Statistical analysis of bone marrow cells stained and analysed as
in A. No significant differences based on genotypes are observed; n=3-4; error bars=SD.
doi: 10.1371/journal.pone.0080312.g004
Multi-Gene Knockdown by RNAi
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fractions for the expression of Ebf1 revealed no significant
differences in the amount of mRNA even in vavCre::Rosa26RNAi/+
versus vavCre:: Rosa26RNAi/RNAi mice (Fig. 5B). Since RNAi can
also inhibit protein translation, we tested the protein levels of
early B cells. As the number of cells after fractionation is too
low to allow for testing of individual fractions, we sorted
B220+CD43+ fractions A - C, and subjected those to Western
blot analysis. Using a pan Ebf antibody recognising Ebf1, Ebf2
and Ebf3, we could detect comparable amounts of Ebf protein
in cells from all genotypes. For control, bone marrow
mononuclear cells were depleted of B220+ cells and included in
the assay. No band was detected in these cells, confirming that
no Ebf protein is expressed in hematopoietic cells besides Ebf1
in B cells (Figure 5C). Quantification of the protein amount by
densitometry confirmed this observation by showing that no
significant differences in Ebf protein levels exist based on the
various genotypes (Figure 5D). Therefore we conclude that
although the transgene mediates down-regulation of Ebf
proteins in cell culture, and it is expressed at high levels in B
cells from transgenic mice, its expression does not affect Ebf1
protein levels in vivo.
No alteration in cerebellar cyto-architecture in the
Ebf2GFPiCre::Rosa26RNAi line
Previous studies have clearly indicated that targeted deletion
of one member of the Ebf gene family (Ebf2) impairs cerebellar
development. In particular, cerebellar Purkinje cells (PCs) are
decreased in number affecting the size and lobulation of the
null cerebellum. One PC subpopulation is selectively reduced,
and PC migration into the cerebellar cortex is impaired or
delayed [21,37]. Ebf2 exerts an autocrine/paracrine control
over PC survival by activating Igf1 gene expression [27]. In
light of these previous findings, we tested the combined effect
of Ebf1-3 down-regulation on cerebellar development. This
analysis was conducted on the adult (P60) progeny of an
Ebf2Cre x Rosa26RNAi/+ cross. Ebf2-Cre is activated at the outset
of PC development, and robust Cre levels are detected in the
cerebellar primordium as early as E11.5 [26]. This transgene
marks the PC lineage, as shown by genetic fate mapping (A.B.,
unpublished observations). Our results clearly indicate that
Ebf2Cre::miRNA+/- mice feature no major cerebellar defects
(Figure 6A-D). DAPI staining indicated that cerebellar
lobulation is unaffected by RNAi activation in PC progenitors.
Moreover, transgenic PCs express normal levels of Calbindin
(CaBP), a Ca2+ binding protein whose levels decrease rapidly
upon PC degeneration. Finally, RNAi-expressing PCs exhibit a
normally branched dendritic tree. Thus, no obvious
abnormalities were scored in RNAi-expressing cerebella.
Expression of Gfp and the miRNA-transgene are
correlated but do not influence Ebf protein levels
The data indicate a clear discrepancy between the
functionality of the construct in vitro and in vivo. One possible
explanation is an insufficient expression level of the transgene.
So far we have analysed Gfp-positive cells as one bulk
population, but as shown in Figure 3A, the expression of Gfp
shows a broad spectrum, from high to low expression in largely
three distinct populations. This offers the possibility to analyse
these populations individually, to examine if expression-related
effects are masked in the bulk analysis. To this end, we
isolated low, middle and high Gfp-expressing cells in addition
to Gfp-negative cells by flow cytometry from vavCre::miRNA+/-
and vavCre::miRNA-/- mice. Interestingly, the percentage of cells
in the respective gates does not differ between these two
genotypes, but the expression of Gfp is clearly higher in
vavCre::miRNA-/-, reflecting the presence of two instead of one
allele of the transgene (Figure 7A).
The expression of the transgene in these sorted populations
was analysed in qPCR by primers spanning from the 3'-end of
Gfp to the last inserted miRNA sequence. As shown in Figure
7B, Gfp-negative cells from all examined genotypes displayed
no detectable expression of the transgene, while cells from
gates 2 - 4 show increasing expression of the transgene
(Figure 7B), revealing a correlation in the expression of the
transgene with Gfp. Therefore, if expression plays a role, we
might be able to see an influence on Ebf1 protein levels in the
most highly expression populations. However, western blot
analysis of cells sorted according to the gates showed that
Ebf1 was present in the different fractions at comparable levels
(Figure 7C), indicating that too low expression of the transgene
alone does not explain the observed inefficiency in vivo.
Discussion
RNAi has evolved as a means to down-regulate the
expression of single target genes in vivo [38]. Initially, short-
hairpin RNAs were driven by RNA polymerase III-dependent
promotors to affect the expression of a single target gene
[39–44]. Tissue-specificity can be achieved via the disruption of
the promotor by a neomycin-resistance cassette flanked by
loxP sites [45–47]. However, neither does this system allow to
incorporate a marker gene, nor to choose the activating
potential of the promotor. When it was found that over-
saturation of the cellular shRNA/miRNA pathway was sufficient
to cause morphologic changes and even fatality in mice, it
became clear that a regulated expression was important in vivo
[48]. At the same time, shRNA sequences were discovered that
are embedded in more complex RNAi transcripts, which are
driven by RNA polymerase II, opening the possibility of tissue-
specific expression and inclusion of a marker gene [29,49,50].
Among those, miRNA30 was first shown to mediate inhibition
of cognate mRNAs with natural as well as designed miRNA
sequences [51]. This system was developed further, and now
allows the down-regulation of target RNAs in a tissue-specific
and, by adding a doxycycline-inducible promoter, reversible
manner [52–54].
In some situations however, as to overcome genetic
redundancy or to inhibit more than one signalling pathway, it is
desirable to inhibit several genes concomitantly. The miR155
precursor is embedded within the third exon of the non-coding
BIC gene, and the miR155 precursor together with flanking
regions is sufficient to confer the oncogenic activities of BIC/
miR155 [55,56]. Based on this, a polycistronic expression
vector for RNA polymerase II was developed, in which the
flanking regions, which are subject to cleavage by the RNAse
Drosha, are used to concatemerise sequences encoding
Multi-Gene Knockdown by RNAi
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Figure 5.  Expression of the transgene does not interfere with Ebf1 levels in vivo.  (A) Single cell suspensions from bone
marrow of mice with the same genotypes as before were prepared and stained for B220/CD43 and CD24/BP1. Cells were gated in
flow cytometry for FSC/SSC and as B220+CD43+ as indicated in the left panel in a representative example. The right panel shows
the gates used for sorting of cells from fraction A (B220+CD43+CD24-BP-1-), B (B220+CD43+CD24+BP-1-) and C
(B220+CD43+CD24+BP-1+). These B cell fractions were sorted from all the genotypes used throughout this study. (B) Sorted cells
from different B cell fractions of the indicated genotypes were subjected to qPCR analysis of Ebf1. All values were normalised to
HPRT and the expression of Ebf1 in wild-type cells was set to 1 in each case; n=3-4; error bars=SD. (C) B220+CD43+ cells were
sorted from total bone marrow of mice with the indicated genotypes and used for analysis of expression of Ebf1 by Western blot
(Fractions A-C). Bone marrow from wild-type mice was depleted of B220+ cells (B220- BMMNC) and used as negative control, β-
actin is used as loading control. (D) Measurement of the amount of protein present in the B cell fractions and control as depicted in
C using ImageJ; n=3-4; error bars=SD, ** p<0.01.
doi: 10.1371/journal.pone.0080312.g005
Multi-Gene Knockdown by RNAi
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shRNAs [25]. At least two different synthetic shRNAs can be
expressed from a single transcript and coupling to a marker
gene like Gfp is possible without compromising the efficiency of
the system. We used this framework to incorporate sequences
directed against Ebf1, Ebf2 and Ebf3 and observed a strong
down-regulation upon ectopic expression but also of the
endogenous genes, allowing us to establish a redundant role of
these proteins in the support of hematopoietic stem cells [24].
As these constructs also worked in various other cellular
contexts [26,27], we wanted to extend the system and to
overcome the limitations of cell culture and retroviral infections.
The most striking finding of our experiments is that an RNAi
construct that mediates down-regulation of cognate RNA very
efficiently in cell culture does not have a biological effect in
vivo. Several possibilities with different likelihoods can explain
this discrepancy. One of our major concerns was the level of
expression necessary to achieve a down-regulation in vivo.
Originally, one of the reasons for choosing RNA polymerase III
for the expression of shRNAs was the high level of expression
that can be achieved. Therefore, we did not want to rely on the
expression mediated by the endogenous Rosa26 locus, which
ranges from low to mid level, depending on cell type, but is not
near typical RNA polymerase III or viral promotor driven
expression [57,58]. Therefore, we chose the synthetic CAG
promotor, which is among the strongest inducers of eukaryotic
expression known [31]. We do observe a good inducibility of
Gfp in ES cells and particularly in hematopoietic cells after
vavCre mediated activation of the transgene. In this case, the
expression results in a shift of three log units in flow cytometry,
and can be further enhanced to a shift over four logarithmic
units by crossing the transgene to homozygosity. This
expression is very likely to be higher than the levels achieved
Figure 6.  No relevant alterations in the adult cerebellum as a result of RNAi activation in the early cerebellar
primordium.  (A-B) Low magnification DAPI stainings of postnatal day 60 cerebella. Normal lobulation in the RNAi-expressing
cerebellum (Ebf2Cre::Rosa26RNAi/+, panel B), compared to a Cre- control (A). (C-D) Sagittal sections of adult cerebella stained for the
Purkinje cell (PC)-specific marker calbindin (CaBP, red) and for Gfp. RNAi-expressing PCs (Gfp+, panel D) develop normal somata
and dendritic arbors positive for CaBP. Panel E (normal control) shows sagittally sectioned CaBP+ PCs from an
Ebf2Cre::Rosa26YFP/YFP mouse. Size bars: B, 200 µm; E, 25 µm.
doi: 10.1371/journal.pone.0080312.g006
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Figure 7.  Expression levels of Gfp and transgene correlate, but do not influence Ebf protein.  (A) Bone marrow cells from
mice with the indicated genotypes were sorted as negative (G1), low (G2), middle (G3) and high (G4) for the expression of Gfp. (B)
Cells sorted according to the gates in (A) were analysed for the expression of the miRNA by qPCR. Additionally, bone marrow was
isolated from control mice as indicated and used in this analysis. n=3-4; error bars=SD, ** p<0.01, *** p<0.001. (C) Cells sorted
according to the gates in (A) were analysed for the presence of Ebf1 protein by western blot. β-actin is used as loading control and
the genotypes of the donor mice are indicated. For western blot, three biological replicates were pooled and analysed together.
doi: 10.1371/journal.pone.0080312.g007
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using the tet-transactivator to down-regulate p53 [52].
Therefore, and as Ebf genes are not expressed at very high
levels (own unpublished data), we consider it very unlikely that
too low expression of the transgene is the reason for the lack of
down-regulation of Ebf proteins. The expression of the
transgene at different levels allowed us to study a potential
influence on Ebf protein levels closer. The analysis of cells
expressing GFP not at all, or at low, middle or high levels
shows that the transgene encoding is detectable at
corresponding levels, which is not surprising, given that both
are encoded by one mRNA. This also shows that the transgene
encoding for the miRNA sequences is really present in the
transgene. However, no changes in Ebf protein level can be
detected, not even in the highest expressing cells, ruling out
that a potential effect is masked in the bulk analysis of Gfp-
positive cells and showing that the observed expression levels
alone do not explain the lack of down-regulation. Furthermore,
a higher expression of the transgene in homozygous
transgenic animals, but no down-regulation of Ebf proteins in
these mice argues against a dose-dependent effect.In addition,
we conclude that expression of the transgene from the CAG
promotor does not saturate the miRNA/shRNA machinery, as
miRNAs control many aspects of the development of
hematopoietic cells, but we do not observe any phenotypic
changes [35].
A second possibility might be problems with the processing
of a complex polycistronic mRNA in vivo. To generate the
knock-in mice, we used exactly the same DNA construct as in
the retroviral vector used for the infection of cultured murine
and human cells. Therefore, since cells of the same species
were used, differences in the processing machinery between
cultures cells and transgenic mice seem rather unlikely.
Additionally many studies show that the basic RNAi machinery
is ubiquitously expressed. The second possibility is that the
basic machinery is the same in vitro and in vivo, but the
artificial RNAi construct generated poses more problems in its
correct processing than endogenous miRNAs. Chaining of
more than three shRNA sequences strongly decreases the
efficiency in mediating down-regulation for each shRNA and
the expression of Gfp is attenuated by shRNA chaining,
presumably due to increased processing (data not shown).
Together, this might indicate that the construct is on the border
of loosing its effectiveness due to its complexity. Again, the
expression of Gfp in vitro and in vivo and the down-regulation
of Ebf proteins in cultured cells argues against this possibility,
although we consider it more likely than the two afore
mentioned possibilities.
A third general possibility is the design and efficiency of the
RNAi sequences used to inhibit the Ebf proteins. The precise
sequence requirements for efficient RNAi are not well
understood [59], although it is known that thermodynamic
asymmetry, low G/C content and a strong bias for A/U at the 5'
end of the guide strand are important [60–62]. We have tested
the RNAi sequences for down-regulation in cultured cells by
transfection of the shRNA encoding plasmid and by retroviral
infection of primary cells for efficient down-regulation of
transfected and endogenous Ebf proteins [24]. In both cases
however, the RNAi transcripts result from a multitude to several
origins of expression (plasmids / retroviral integration sites), but
not from a single genomic locus as is the case in the transgenic
mice. In fact it is this aspect where the biggest differences
between the in vitro and in vivo approach occur. Based on a
large scale approach, it has been estimated that only 3% of all
possible RNAi sequences for a particular gene elicit efficient
knockdown at the level of single copies [28]. Of all the possible
explanations mentioned here, we consider problems with the
design and the efficiency of the RNAi sequences as single
genomic copies most likely to explain the discrepancy between
in vitro and in vivo, i. e. the absence of a detectable down-
regulation of Ebf proteins.
In summary, we have used a new miR155-based system to
explore the potential to knockdown the expression of several
genes simultaneously. This approach was successfully in vitro,
however, its direct translation in vivo did not result in the
expected down-regulation. We think that the most likely
explanation for this discrepancy lies in the efficiency of the
RNAi sequences as single genomic copies. This, together with
the complexity of the whole RNAi transcript, consisting of three
short hairpins and Gfp, likely results in an overall efficiency that
is too low to detect and that potentially can be compensated
for. We do not think that the overall expression or differences in
the endogenous basic miRNA/RNAi machinery are likely
explanations. The data presented here clearly show that
expression of the transgene from the CAG promoter is
compatible with a normal function of the basal miRNA/RNAi
machinery in hematopoietic cells, and the miR155 framework
works well in the context of inducible expression from the
Rosa26 locus as shown by Gfp. The data presented here
provide the foundation for future work on the simultaneous
knockdown of several genes in vivo, as the problems
concerning the efficiency of the RNAi sequences can be
overcome [59].
Experimental Procedures
Generation of transgenic mice
Two different sequences to inhibit Ebf1, Ebf2 and Ebf3
(RNAi-a and RNAi-b) were excised together with EmGFP from
the pcDNA6.2-GW/EmGFP vector (Invitrogen, [24]), and
inserted into the XbaI site of the pRTS targeting vector (kindly
provided by D. Calado, Immune Disease Institute Inc., Boston,
MA). Mouse ES cells derived from C57Bl/6 x 129S6/SvEvTac-
F1 strains (IDG3.2) were electroporated with this construct and
colonies were isolated in the presence of 170 µg/ml G418
(Gibco). DNA extraction and Southern Blots were performed as
described [63]. The correct insertion of the targeting sequences
was analysed using an external 550 bp 5' probe and an internal
Gfp probe of 723 bp. The 5' probe was cut from the
pRosa26-5-pBS KS plasmid using EcoRI and PacI, the Gfp
probe was isolated from the pcDNA6.2-GW/EmGFP vector
using DraI. Hybridisation was carried out for 16 hours at 65°C
in Church buffer (0.4 M Na2HPO4), membranes were washed 3
x 10 min at 58°C in wash buffer (0.2 x SSC, 0.5% SDS) and
bands were detected using a phospoimager (Fuji Bas 1000).
Two correctly targeted clones representing RNA-a and RNA-b
constructs were injected into C57BL/6 blastocysts that were
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implanted into pseudopregnant females. Chimeric mice were
bred to obtain germ-line transmission. Two male chimera
(80%) corresponding to the RNA-a clone were selected to get
heterozygous mice. Mutant mice were backcrossed with
C57Bl/6 wild-type mice for more than 6 generations. All
experiments involving animals were designed in agreement
with the stipulations of the San Raffaele Institutional Animal
Care and Use Committee, the Helmholtz Zentrum München
and the Regierung von Oberbayern. The protocol and all
experiments involving animals was approved by the ethics
committees of the afore mentioned institutions. All efforts were
made to minimise animal suffering.
Genotyping
For genotyping of mice tails were digested for at least 1 h in
lysis buffer [FirePol buffer B (Solis BioDyne), 1.25 mM MgCl2,
50 µg/ml proteinase K] at 55 °C and inactivated for 15 min at
95 °C. PCR was carried out with genomic DNA; 20 pmol of
each primer were used, for the miRNA line (5'-Rosa fwd 5-
´GAGTTCTCTGCTGCCTCCTG-3´, CAG rev 5´-
TGAACTAATGACCCCGTAATTG-3´, 3'Rosa rev 5´-
AGGAAAGGGAAAATGCCAAT-3´ using FirePol (Solis
BioDyne) under these conditions: 31 cycles of 94 °C for 45 sec,
60 °C for 45 sec, 72 °C for 1 min to amplify products of 600 bp
for wild-type and 290 bp for the mutant allele; for R26RYFP line
(R523 5’-GGAGCGGGAGAAATGGATAT-3’, R26F2: 5’-
AAAGTCGCTCTGAGTTGTTAT-3’, oIMR 316 5’
AAGACCGCGAAGAGTTTGTC-3’) under these conditions: 35
cycles of 94 °C for 30 sec, 58 °C for 1 min, 72 °C for 1 min to
amplify products of 600 bp for wild-type and 320 bp for the
knock-in allele; for Ebf2GFPiCre line (F 5’-
ATGGTGCCAAGGATGACTC-3´, R 5’-
CCTCGAGCAGCCTCACCA-3´) under these conditions: 30
cycles of 94 °C for 30 sec, 58 °C for 30 sec, 72 °C for 30 sec to
amplify a 200 bp product corresponding to the transgene.
Cell-culture, Transfections, Plasmids
HEK293T cells were kept under standard conditions in
DMEM medium (+ 10% FCS, 1% Pen/Str/Glu; Gibco), and
transfected using polyethylenimine (Gibco) according to
standard protocols. For ectopic expression Ebf1, Ebf2 and Ebf3
were cloned into the pcDNA3.1 vector (Invitrogen) in frame with
an N-terminal Flag-tag (Sigma).
Flow cytometry, Antibodies
For flow cytometry single cell suspensions were prepared by
trypsinising ES cells or by aspirating bone marrow according to
standard procedures. Isolated cells were blocked for unspecific
binding using CD16/32 and incubated with either biotinylated or
directly fluorochrome-conjugated antibodies. Cells were
measured or sorted using either an LSRFortessa or a
FACSAriaIII (BD Biosciences) and data were analysed using
FACSDiva (Becton Dickinson GmbH) and FlowJo 9.3 (Treestar
Inc.) software. For depletion of dead cells propidium iodide was
used. Antibodies directed against the following markers were
obtained from BD Biosciences: B220 (RA3-6B2) and CD43
(RM4-5), BP-1 (6C3), CD24 (30-F1), CD16/32 (=FcγRII/III;
2.4G2).
Isolation of RNA and Quantitative RT-PCR
mRNA was isolated using peqGOLD TriFastTM (Peqlab)
according to manufacturer’s instructions, cDNA was
synthesised using SuperScript II reverse transcriptase
(Invitrogen) and the oligo-dT primer (Roche). qPCR reactions
were performed in duplicate with SYBR Green I Master in a
LightCycler® 480II (Roche) with standard conditions: 95 °C for
10 min followed by 45 cycles of 95 °C for 10 s, 65 °C for 10 s
and 72 °C for 10 s. Primer sequences: Hprt fwd 5´-tgc tgg tga
aaa gga cct ctc g-3´, rev 5´-tct ggg gac gca gca act ga-3´; β-
Actin fwd 5'-tgt ggt ggt gaa gct gta gc-3', rev 5'-gac gac atg gag
aag atc tgg-3'; Ebf1 fwd 5´-ggg gac agt gca gat ggt aa-3´, rev 5
´-caa ctc act cca gac cag ca-3´; Gfp fwd 5'-acc tac ggc gtg cag
tgc ttc agc-3', rev 5'-gtc ctc gat gtt gtg gcg gat ctt g-3'; miRNA-
fwd: 5'-ggc atg gac gag ctg tac aa-3', miRNA-rev3: ctc tag atc
aac cac ttt gt-3'. Three independent measurements were
performed for each qPCR analysis, error bars represent the
standard deviation of the mean. The comparative CT method
was used to calculate the expression levels of RNA transcripts,
and the quantified individual RNA expression levels were
normalised for the respective β-actin expression levels, unless
stated otherwise. Since we measured the relative RNA
expression levels, the indicated expression levels were set as 1
or 100.
Histological procedures
Postnatal mice were anaesthetised with Avertin (Sigma, St
Louis, MO, USA) and perfused with 0.9% NaCl followed by 4%
paraformaldehyde (PFA). Tissues were fixed with 4% PFA,
cryoprotected in 30% sucrose overnight, embedded in OCT
(Bioptica), sectioned on a cryotome (18 μm). Cryosections
were immunostained with the following antibodies: rabbit or
mouse anti-calbindin (1:1000, Swant, Bellinzona, Switzerland);
rabbit anti-GFP (1:700; Invitrogen); chicken anti-GFP (1:500;
Abcam, Cambridge, UK).
Statistics
P-values were determined with the Student’s two-tailed t-test
for independent samples, assuming equal variances on all
experimental datasets.
Immunoblotting, Antibodies
Protein isolation and immunoblotting was carried out
according to standard procedures, antibodies used were α-
panEbf [24], α-β-Actin (AC-74, Sigma), α-Flag (M2, Sigma),
The secondary α-mouse-IgG.HRP antibodies were obtained
from Sigma, the secondary α-rat-IgG + IgM.HRP antibody was
purchased from Jackson Immuno Research. Bands in western
blot experiments were quantified using the open source
software ImageJ (http://rsb.info.nih.gov/ij/; W. S. Rasband, NIH,
National Institutes of Health, Bethesda, MD).
Supporting Information
Figure S1.  Schematic overview of the DNA sequences
used for RNAi. (A) The structure of the transcripts of Ebf1,
Ebf2 and Ebf3 is depicted including 5'- and 3'-UTR. Protein
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domains encoded by the transcripts are indicated above (HLH
= helix-loop-helix domain) and the beginning and end of the
coding sequence are given underneath in base pairs relative to
the start site. The sequences used to inhibit the individual
members and their positions are plotted against the transcripts.
Two sequences are indicated for each gene, as two different
RNAi constructs have been generated, and their identifying
numbers are given underneath. (B) Schematic representation
of the organisation of the RNAi used for the transgene. Grey
boxes represent the flanking region from miR155, and the
numbers within the loops indicate the Ebf gene against which
the sequences at this position are directed. The composition of
the two constructs used for RNAi is given below.
(TIF)
Figure S2.  Down-regulation of Ebf1, Ebf2 and Ebf3 by a
single RNAi construct. To analyse the efficiency and
specificity of bioinformatically predicted sequences to down-
regulate the expression of Ebf1, Ebf2 and Ebf3, HEK293T cells
were transfected with expression plasmids encoding the
individual Ebf proteins together with an N-terminal Flag tag.
Expression vectors containing the shRNA sequences either
alone or in combination were co-transfected, and 48 h after
transfection cells were harvested and analysed by Western
blot. α-Flag antibody was used to detect Ebf expression levels,
and α-actin as loading control. Mock is referring to a co-
transfection of the empty parental vector (pcDNA6.2-GW/
EmGFP), no RNAi leaves out the shRNA containing vectors.
(TIF)
Figure S3.  Analysis of B cell fractions A - C in Rosa26RNAi
transgenic mice. Single cell suspensions from bone marrow of
mice with the indicated genotypes were analysed for the
percentage of early B cell fractions. Cells were stained with
propidium iodide, B220, CD43, and gated for FSC/SSC and as
PI negative, and B220 CD43 double positive. The gating
window and the percentage of cells are shown. Cells were
further stained for BP-1 and HSA/CD24, and analysed for
fractions A -C in detail (Figure 4). Representative examples of
the indicated genotypes are shown. The statistical analysis of
fraction A - C in Figure 4B is referring to this setting.
(TIF)
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